Category: Bellus Health

  • Bayer’s pipeline takes a hit as it drops eliapixant

    Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision comes right on the heels of the FDA’s rejection of Merck & Co’s rival oral P2X3 antagonist gefapixant, which was also attributed to concerns about the safety of […]

  • FDA stifles Merck’s cough drug gefapixant, asking for more data

    The FDA has issued a complete response letter (CRL) to Merck & Co’s gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with its rival eliapixant drug. Gefapixant is still out in front in the non-narcotic, orally administered selective P2X3 receptor antagonist class – having secured […]

  • Bayer’s eliapixant hits the right notes in PAGANINI cough study

    Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co’s rival drug gefapixant. The drugmaker said last month that the PAGANINI study hit its main objective, which was to reduce the average cough frequency compared to placebo after […]

  • Chasing Merck & Co, Bayer builds case for cough drug eliapixant

    Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co’s gefapixant, which was filed for approval in March. The orally-active P2X3 receptor antagonist, also known as BAY1817080, hit the main objective of the study, which was […]